pomalidomide has been researched along with masitinib in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (masitinib) | Trials (masitinib) | Recent Studies (post-2010) (masitinib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 127 | 18 | 104 |
| Protein | Taxonomy | pomalidomide (IC50) | masitinib (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.5 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlowski, RZ | 1 |
1 review(s) available for pomalidomide and masitinib
| Article | Year |
|---|---|
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |